Cantor Fitzgerald analyst Louise Chen downgraded Aclaris Therapeutics to Neutral from Overweight without a price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACRS:
- Aclaris Therapeutics price target lowered to $8 from $29 at BTIG
- Aclaris Therapeutics downgraded to Market Perform from Outperform at Leerink
- Aclaris Therapeutics downgraded to Neutral from Overweight at Piper Sandler
- Aclaris Therapeutics downgraded to Hold from Buy at Stifel
- Aclaris Therapeutics downgraded to Market Perform at William Blair